Allergy Therapeutics PLC (AGYTF)
0.02
0.00 (0.00%)
USD |
OTCM |
Jun 03, 16:00
Allergy Therapeutics 1 Year Total Returns (Daily): -88.57% for June 3, 2024
1 Year Total Returns (Daily) Chart
Historical 1 Year Total Returns (Daily) Data
Date | Value |
---|---|
June 03, 2024 | -88.57% |
May 31, 2024 | -88.57% |
May 30, 2024 | -88.57% |
May 29, 2024 | -88.57% |
May 28, 2024 | -88.57% |
May 24, 2024 | -88.57% |
May 23, 2024 | -88.57% |
May 22, 2024 | -88.57% |
May 21, 2024 | -88.57% |
May 20, 2024 | -88.57% |
May 17, 2024 | -88.57% |
May 16, 2024 | -88.57% |
May 15, 2024 | -88.57% |
May 14, 2024 | -88.57% |
May 13, 2024 | -88.57% |
May 10, 2024 | -88.57% |
May 09, 2024 | -88.57% |
May 08, 2024 | -88.57% |
May 07, 2024 | -88.57% |
May 06, 2024 | -88.57% |
May 03, 2024 | -88.57% |
May 02, 2024 | -88.57% |
May 01, 2024 | -88.57% |
April 30, 2024 | -88.57% |
April 29, 2024 | -88.57% |
Date | Value |
---|---|
April 26, 2024 | -88.57% |
April 25, 2024 | -88.57% |
April 24, 2024 | -88.57% |
April 23, 2024 | -88.57% |
April 22, 2024 | -88.57% |
April 19, 2024 | -88.57% |
April 18, 2024 | -88.57% |
April 17, 2024 | -88.57% |
April 16, 2024 | -88.57% |
April 15, 2024 | -88.57% |
April 12, 2024 | -88.57% |
April 11, 2024 | -88.57% |
April 10, 2024 | -88.57% |
April 09, 2024 | -88.57% |
April 08, 2024 | -88.57% |
April 05, 2024 | -88.57% |
April 04, 2024 | -88.57% |
April 03, 2024 | -88.57% |
April 02, 2024 | -60.00% |
April 01, 2024 | -60.00% |
March 28, 2024 | -60.00% |
March 27, 2024 | -60.00% |
March 26, 2024 | -87.42% |
March 25, 2024 | -87.42% |
March 22, 2024 | -87.42% |
Total Return Definition
The Total return is the change in price over a specific period of time that includes dividends and distributions paid.
1 Year Total Returns (Daily) Range, Past 5 Years
-99.94%
Minimum
Oct 21 2020
497.9K%
Maximum
Oct 21 2021
7.71K%
Average
-27.98%
Median
Sep 18 2023
1 Year Total Returns (Daily) Benchmarks
Adaptimmune Therapeutics PLC | 0.00% |
Biodexa Pharmaceuticals Plc | -84.68% |
Verona Pharma PLC | -44.27% |
NuCana PLC | -82.86% |
Autolus Therapeutics PLC | 55.17% |